The U.S. Department of Health and Human Services said Tuesday it awarded a $25 million contract to Mapp Biopharmaceutical Inc. to fund the manufacture of a small amount of experimental Ebola treatment ZMapp and to speed the drug's development. . The new supply to be funded with the 18-month contract would be used in early-stage clinical studies to test the drug's safety and efficacy, HHS said. The contract can be expanded to a value of up to about $42 million, HHS said.